Key Highlights
- Third quarter loss was USD 0.46 per share against an estimated USD 0.15 loss, on USD 1.14 million revenue.
- Net loss reached USD 46.5 million for the quarter, versus USD 17.5 million in the same period last year.
- Research and development expense rose to USD 14.5 million from USD 6.4 million a year earlier.
- Enrollment in the Phase 3 OPGx-LCA5 trial is complete at eight participants, with first dosing guided for the fourth quarter.
Opus Genetics (NASDAQ:IRD) reported a third quarter 2026 loss of USD 0.46 per share, wider than the USD 0.15 estimated loss. Revenue of USD 1.14 million compared with the USD 1.55 million estimate. Net loss was USD 46.5 million for the quarter and USD 120.1 million for the nine months, against USD 17.5 million and USD 33.1 million in the prior-year periods.
The accumulated Deficit was USD 308.7 million at September 30. The company sold 1,000,000 shares under its prior at-the-market program in the first quarter for gross proceeds of USD 2.3 million, and made no sales under its new program in the first nine months.
Spending Behind the Wider Loss
Research and development expenses were USD 14.5 million for the quarter, up from USD 6.4 million, and USD 36.3 million for the nine months, up from USD 20.4 million. General and administrative expenses were USD 5.9 million in the quarter, compared with USD 5.0 million a year earlier. Stock-based compensation within Research and Development was USD 0.6 million for the quarter, and USD 1.0 million within general and administrative.
The filing's quarterly net loss is larger than the sum of those two expense lines, so non-operating items also affected the result. Readers comparing periods may want to review the full statements for the breakdown.
OPGx-LCA5 Moves Toward Dosing
OPGx-LCA5 targets blindness linked to the LCA5 gene, which affects an estimated 170 patients in the United States and 3,240 globally. The therapy has been accepted into the FDA's Rare Disease Evidence Principles program and has Rare Pediatric Disease, Regenerative Medicine Advanced Therapy and Orphan Drug designations. In July 2026 the company reported alignment with the FDA on a registrational Phase 3 design in eight participants, with a six-month run-in so each serves as their own control.
Enrollment completed in August, and dosing is anticipated to begin in the fourth quarter of 2026 using drug Supply made with the intended commercial processes. The study is designed with more than 90% statistical power to detect a treatment effect of at least seven decibels, and topline data are anticipated by the end of 2027. Earlier data showed restoration of cone-mediated vision in pediatric patients and a maintained response in adults out to 24 months.
OPGx-BEST1, for Best disease and related conditions, is in an open-label Phase 1/2 trial known as BIRD-1. Enrollment in the first dose cohort completed in May 2026 with five participants. In August the company met with the FDA on development and aligned on a potential pivotal endpoint based on microperimetry improvement of at least 3 decibels. An independent monitoring committee earlier recommended advancing the trial without modification after a safety review.
Milestones to Follow
First Phase 3 dosing in the fourth quarter, progress in the BEST1 dose cohorts and the company's financing activity are the items to track, given the rising spending level. Topline LCA5 data by the end of 2027 is the longer-dated marker.






Please wait processing your request...